ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

American Kratom Association Calls on the FDA To Be Fully Transparent and Accountable in Their Safety Alert on Kratom Products

FDA’s most recent safety alert is clearly an unfortunate repeat of the exact mistakes the FDA has made for years on kratom

WASHINGTON, DC, July 29, 2024 (EZ Newswire) -- The FDA’s most recent mistaken and misguided safety alert which warns consumers to not use OPMS Black Liquid Kratom is clearly an unfortunate repeat of the exact mistakes that former HHS Assistant Secretary of Health, Dr. Brett Giroir, previously condemned when he correctly noted that the FDA has been relying upon "embarrassingly poor evidence and data" on kratom.

The American Kratom Association (AKA) calls upon the FDA Commissioner, Robert Califf, to immediately remove the July 26, 2024, consumer warning statement regarding OPMS Black Liquid Kratom until the agency has independently verified the alleged claims regarding the death that they have not conclusively proven to be attributed to this product.

"The FDA safety alert on a kratom product appears to be a new rehash of previously debunked FDA claims that kratom killed nine people in Sweden in 2009, that the FDA cited in their Federal Register Notice in 2016 to justify its recommendation to classify kratom as a Schedule I substance that researchers eventually determined were actually caused by the mixing of a toxic adulterant, O-desmethyltramadol, into the kratom product that actually caused those deaths," stated Mac Haddow, Senior Fellow on Public Policy at the AKA. "The HHS Assistant Secretary of Health wrote a scathing withdrawal letter on the FDA’s scheduling recommendation, and publicly called out the FDA for using 'embarrassingly poor evidence and data' in trying to schedule kratom."

The most recent FDA safety alert vaguely references a reported kratom death but provides no details or credible evidence that would link that death to the kratom product referenced by the FDA. That safety warning stands in stark contrast to a July 25, 2024, FDA public health alert on elevated levels of lead in a ground cinnamon product where the product was tested by the New York State Department of Agriculture, and then "confirmed by the FDA", with their own testing. 

No such information on the verification of this claim is available in the FDA safety alert for the alleged kratom product issue.

"The consistently unreliable and often false statements about kratom issued by the FDA over the past decade, which is a part of its relentless and misguided pursuit of banning kratom products that is not supported by reliable science, are wrong and Commissioner Califf should hold his agency fully accountable," Haddow stated. "The various autopsy reports that have claimed that kratom is the sole cause of deaths have been thoroughly refuted as incomplete, poorly documented, hastily concluded, or demonstrably incorrect."

The FDA safety alert claims that it is based upon an adverse event report relating to a "person who died after using OPMS Black Liquid Kratom," and stated that it was among many such reports. Yet, in a review of the current data available on the FDA Adverse Events Reporting System (FAERS) Public Dashboard (https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis) those claims cannot be validated.

Plaintiff’s trial attorneys have been openly encouraging clients and other anti-kratom advocates to submit complaints to the FDA on alleged deaths over the past few months and have taken to social media platforms to solicit others to do so. The FDA "safety alert on kratom" appears to be the result of a coordinated effort by those trial attorneys who have a financial interest in litigation against the very company the FDA’s safety alert identifies. Those cases should be tried in the courts, where they belong, and not involve the power of a federal agency to prosecute private claims.

The FDA staff is undermining Commissioner Califf’s own initiative to eliminate health misinformation, which the commissioner himself said "poses the most serious threats to public health today.” The FDA is not exempt from the solemn duty to accurately convey information only after it that has been fully and credibly vetted and proven.

"Commissioner Califf must direct that this current safety warning be immediately and completely removed until the report can be fully evaluated and meaningful discussions with the manufacturer have taken place," concluded Haddow. “Until then, the prior ominous warning by Dr. Giroir remains accurate: the FDA continues to rely on 'embarrassingly poor evidence and data' in relation to kratom issues."

Sources

  1. https://www.sciencedirect.com/topics/neuroscience/o-desmethyltramadol
  2. https://cdn.prod.website-files.com/61858fcfc6543059f0617522/620c13ac9741c266fb08af52_HHS%20Rescission%20Letter%20Dr.%20Giroir%20Aug%2016%202018%20highlighted.pdf
  3. https://x.com/DrGiroir/status/1395874443726102533
  4. https://www.fda.gov/food/alerts-advisories-safety-information/fda-public-health-alert-additional-ground-cinnamon-product-due-presence-elevated-levels-lead
  5. https://www.fda.gov/news-events/speeches-fda-officials/speech-commissioner-robert-m-califf-house-medicine-06162023

About American Kratom Association (AKA)

The American Kratom Association (AKA), a consumer-based non-profit organization, advocates to protect the freedom of consumers to safely consume natural kratom as a part of their personal health and well-being regimen. AKA represents the nearly 20 million Americans who consume kratom safely each year. www.americankratom.org

Media Contact

Mac Haddow
+1 571-294-5978

###

SOURCE: American Kratom Association (AKA)

Copyright 2024 EZ Newswire

See release on EZ Newswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.